Skip to content
Home
About
Ionis Innovation
Back To Main
Overview
Antisense Technology
Optimizing Antisense
Pipeline
Our Medicines
Patients & Community
Back To Main
Overview
Patient Resources
Community Engagement
Patient Experiences
Investors & media
Back To Main
Overview
Newsroom
Back To Main
Investors & Media
Press Releases
InBriefs
Media Center
Stock Information
Back To Main
Investors & Media
Stock Quote & Chart
Analyst Coverage
Ownership Profile
Financials
Back To Main
Investors & Media
SEC Fillings
Annual Reports
Governance
Back To Main
Investors & Media
Governance Documents
Committee Composition
Clawback Policy
RSU Holding Guidelines
Investor Resources
Back To Main
Investors & Media
Investor FAQs
Contact Us
Events
Back To Main
Investors & Media
Events
Careers
Back To Main
Overview
Working at Ionis
Intern Program
Post Doctoral Program
Follow Us
twitter-grey
menu
Home
About
Ionis Innovation
Back To Main
Overview
Antisense Technology
Optimizing Antisense
Pipeline
Our Medicines
Patients & Community
Back To Main
Overview
Patient Resources
Community Engagement
Patient Experiences
Investors & media
Back To Main
Overview
Newsroom
Back To Main
Investors & Media
Press Releases
InBriefs
Media Center
Stock Information
Back To Main
Investors & Media
Stock Quote & Chart
Analyst Coverage
Ownership Profile
Financials
Back To Main
Investors & Media
SEC Fillings
Annual Reports
Governance
Back To Main
Investors & Media
Governance Documents
Committee Composition
Clawback Policy
RSU Holding Guidelines
Investor Resources
Back To Main
Investors & Media
Investor FAQs
Contact Us
Events
Back To Main
Investors & Media
Events
Careers
Back To Main
Overview
Working at Ionis
Intern Program
Post Doctoral Program
Follow Us
twitter-grey
You are now leaving https://www.ionispharma.com to visit
Continue to site
Cancel
ION253
Generation 2.5 antisense drug
ION253, formerly known as IONIS-JBI2-2.5
Rx
.